Hypromellose, also designated hydroxypropyl methyl cellulose, is a partly O-methylated and O-(2-hydroxypropylated) cellulose ether produced from purified cellulose by reaction with methyl chloride and propylene oxide under alkaline conditions. The material is nonionic, hydrates in cold water, and is supplied as white to off-white, odourless, free-flowing granules or powder; the CAS registry number is 9004-65-3. The USP-NF monograph recognises substitution types 1828, 2208, 2906, and 2910, which are differentiated by methoxyl and hydroxypropoxyl content rather than by viscosity. Commercial grade nomenclature combines the substitution type with the nominal apparent viscosity of a 2% (w/w) aqueous solution at 20 °C, giving examples such as HPMC E5, E15, K100LV, K4M, K15M, and K100M. The pharmacopoeial viscosity acceptance is normally 80–120% of label for values below 1,000 mPa·s and 75–140% for 1,000 mPa·s and above, tested by capillary viscometer according to USP <911>. Compendial controls for pharmaceutical-grade material include loss on drying ≤5.0%, residue on ignition ≤1.5%, and a pH of an aqueous preparation typically 5.0–8.0. The powder is hygroscopic; storage above 60% relative humidity may require pre-drying or controlled dispensing because moisture above the loss-on-drying limit can impair powder flow and gravimetric dosing accuracy.

Why Does Substitution Type 2208 Differ from 2910 in Granulation and Matrix Tablets?

Substitution type 2910 has a methoxyl content of 28.0–30.0% and hydroxypropoxyl content of 7.0–12.0%, whereas type 2208 has 19.0–24.0% methoxyl and 4.0–12.0% hydroxypropoxyl. Type 1828, with 16.5–20.0% methoxyl and 23.0–32.0% hydroxypropoxyl, is the most hydrophilic substitution class and is more often applied in aqueous suspending-agent functions. Type 2906, at 27.0–30.0% methoxyl and 4.0–7.5% hydroxypropoxyl, occupies an intermediate position. The practical consequence in solid oral processing is that 2910 low-viscosity grades hydrate rapidly and yield low-solids binder solutions with predictable spray distribution, while 2208 high-viscosity grades produce high gel strength, slower erosion, and more controlled drug release from matrix tablets. A granulation designed around 2910 E5 cannot be replaced with 2208 K100M without altering wet mass torque, granule size distribution, compression hardness, and dissolution kinetics.

For oral non-sterile grades, microbial enumeration is tested by USP <61> and specified organisms by USP <62>; residual solvents are controlled by USP <467> with ICH Q3C, and elemental impurities are risk-assessed under ICH Q3D with USP <232>/<233>. The particle-size distribution and bulk density are not fully harmonised across the compendia and are grade-specific; laser diffraction per USP <429> or sieve analysis per USP <786> is used for release. Bulk density typically falls within 0.25–0.65 g/cm³, but fine and coarse grades differ, and the selection is governed by the downstream charging system and segregation tendency in dry blends.

Aqueous high-shear granulation with HPMC E5 or E15 binder solutions is typically performed with binder concentrations of 2–5% (w/w). The solution is delivered through a peristaltic pump and binary nozzle into a high-shear mixer operating at impeller tip speeds of 3–8 m/s; binder addition rate is adjusted against torque or impeller power because HPMC increases wet mass consistency rapidly. Interparticle liquid bridges from HPMC improve granule compactibility but can also produce overwetting and shoulder formation on tablet press tooling if the final granule moisture exceeds approximately 3.0% after drying. Fluid-bed drying is commonly run with inlet air at 60–80 °C until loss on drying is below the target, followed by dry screening through 1.0–2.0 mm screens. The nonionic character of HPMC minimises electrostatic complexation with weakly basic actives, and the polymer remains unionised over pH 3–11, so wet granulation fluids do not require ionic strength adjustment for chemical stability. Tablet compression hardness and disintegration should be evaluated with USP <701>; drug release for modified-release formulations is tested by USP <711> in 900 mL of pH 1.2, 4.5, and 6.8 dissolution media using Apparatus 2 at 50–100 rpm.

Hypromellose Film Coating, Matrix Hydration, and Scale-Up Process Boundaries on Production Lines

Film coating uses low-viscosity HPMC 2910 or 2906 dispersions at 5–12% solids. Pan speed, inlet/outlet temperature, and spray rate are calibrated against solution viscosity and atomization air pressure; a binary nozzle with an orifice near 0.8 mm and atomization air pressure of 0.3–0.8 MPa reduces spray drying and overspray. Cosmetic sealing may require 2–4% weight gain, whereas functional moisture barriers or taste masking may require 6–10% depending on tablet porosity and edge attrition. Coating defects such as orange peel, bridging, and edge failure are governed by the ratio of spray rate to pan-side evaporation; if coating solution viscosity rises because of cooling below 20 °C or evaporation, spray droplet size changes and film uniformity is lost. For modified-release matrices, HPMC 2208 grades are incorporated at 20–50% of tablet mass and compressed to hardness values of 80–200 N. Gel-layer formation after media contact controls release over 8–24 h depending on polymer content, viscosity grade, tablet geometry, and agitation intensity. The nominal viscosity labels correspond to apparent viscosity values of 4,000, 15,000, and 100,000 mPa·s for K4M, K15M, and K100M, respectively, at 2% concentration and 20 °C; these values are nominal, and HPMC solutions are shear-thinning, so capillary or rotational viscometer data must be interpreted with the test geometry. High-shear blending of high-viscosity HPMC with fine active particles should be monitored for segregation because the polymer has a different particle size and bulk density; blending times above 30 min may increase static charge and demixing. Twin-screw melt extrusion of HPMC is not a standard thermoplastic process; if melt-assisted granulation is attempted, barrel temperature and plasticizer selection must avoid exceeding the cellulose ether degradation threshold, and published process data for high-viscosity grades in hot melt extrusion is limited.

For parenteral and ophthalmic compounding, low-viscosity hypromellose grades such as E3 and E5 are selected because their solutions approach Newtonian behaviour and filter through 0.22 µm sterilising-grade membranes. Solution preparation begins by dispersing the powder in hot water at 80–90 °C to prevent lump formation, followed by cooling to ≤25 °C under agitation; the higher-temperature dispersion step does not dissolve the polymer but allows even hydration upon cooling. Injectable-grade material is specified for low bacterial endotoxin and is tested by USP <85>; release for injectable use requires sterility testing according to USP <71> and particulate matter control according to USP <788> or <789>. Terminal sterilisation of high-viscosity HPMC solutions may alter viscosity through chain scission, and published data for terminal sterilisation of every grade is limited; therefore, aseptic filtration of low-viscosity grades is preferred where the formulation permits. The nonionic polymer tolerates electrolytes, but high ionic strength can reduce hydration and increase solution cloudiness; compatibility with preservatives such as benzalkonium chloride should be evaluated by clarity and viscosity retention under ICH storage conditions. Residual monomer and solvent controls for injectable use are anchored to ICH Q3C, and elemental impurities are risk-assessed under ICH Q3D with USP <232>/<233>.

If Thermal Gelation and Nonionic pH-Independent Hydration Are Required, How Does HPMC Compare with MC, HPC, CMC-Na, and Gelatin?

HPMC differs from methylcellulose primarily because the hydroxypropyl substituent modifies thermal gelation and reduces surface tension. Methylcellulose hydrates in cold water and gels at a lower cloud point than most HPMC grades, which makes HPMC more tolerant of low-level organic cosolvents and slight temperature rises during coating. Hydroxypropyl cellulose is soluble in water and polar organic solvents and is more thermoplastic, but HPMC provides higher gel strength at equivalent concentration in sustained-release matrices. Sodium carboxymethyl cellulose is anionic, pH- and cation-sensitive, and can bind weakly basic actives; HPMC remains nonionic across pH 3–11, avoiding ionic complexation. Gelatin forms firm gels on cooling and is still used for capsule shells and tablet binding, but it requires chilled processing and mammalian tissue sourcing controls; HPMC forms thermoreversible aqueous gels that can be used for plant-based capsule shells and pH-independent matrix systems. At equivalent 2% concentration, K100M generates a low-shear apparent viscosity approximately 20,000-fold greater than E5, so mixing, deaeration, and transfer equipment must be selected accordingly.

In hard-shell capsule manufacturing, HPMC solutions are held at 28–32 °C to avoid premature thermogelation before pin dipping, and solution viscosity is maintained in the range 1,000–2,500 mPa·s depending on pin diameter and line speed. The resulting capsule shell is free of animal protein and less prone to aldehyde-mediated cross-linking than gelatin, but dissolution may be slower in pH 1.2 media; dissolution method suitability is assessed with USP <711> and, where cross-linking is suspected, with an appropriate enzyme-mediated protocol before release testing. In granulated and tableted products, HPMC contact with strongly oxidising agents or prolonged high-shear processing at temperatures above the glass transition of the dried polymer can lead to chain scission or discoloration; such combinations should be excluded unless forced-degradation data demonstrate acceptable retention of viscosity and dissolution.